SDF-1 Blockade Enhances Anti-VEGF Therapy of Glioblastoma and Can Be Monitored by MRI()()

Despite the approval of antiangiogenic therapy for glioblastoma multiforme (GBM) patients, survival benefits are still limited. One of the resistance mechanisms for antiangiogenic therapy is the induction of hypoxia and subsequent recruitment of macrophages by stromal-derived factor (SDF)-1α (CXCL-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Lei, Stafford, Jason H., Liu, Shie-Chau, Chernikova, Sophia B., Merchant, Milton, Recht, Lawrence, Martin Brown, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2016
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149063/
https://www.ncbi.nlm.nih.gov/pubmed/27940247
http://dx.doi.org/10.1016/j.neo.2016.11.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5149063/
https://www.ncbi.nlm.nih.gov/pubmed/27940247
http://dx.doi.org/10.1016/j.neo.2016.11.010

Ejemplares similares